What Does CJC-1295 Do? Mechanism and Research Overview
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) that has attracted sustained attention in peptide research. Unlike endogenous GHRH, which degrades rapidly in circulation, CJC-1295 is engineered to resist enzymatic breakdown, extending its biological activity considerably. This guide covers what the research shows about how CJC-1295 works, what it does at the pituitary, and how researchers study it alongside other peptides.
The Basics: What Is CJC-1295?
CJC-1295 is a 29-amino-acid peptide that mimics the first 29 residues of endogenous GHRH. It was developed to address one of the key limitations of native GHRH: a plasma half-life of only a few minutes due to cleavage by dipeptidyl peptidase IV (DPP-IV). The synthetic version incorporates substitutions at positions 2 and 8, plus a C-terminal amidation, to resist that rapid degradation.
Two forms circulate in research discussions. The first is CJC-1295 without DAC (also called Mod GRF 1-29), which has a moderate extended half-life of roughly 30 minutes. The second is CJC-1295 with DAC (Drug Affinity Complex), where a lysine residue is conjugated to allow binding to circulating albumin, extending the half-life to several days. Researchers treat these as distinct compounds with different pulsatility profiles, and the CJC-1295 protocol page covers their differences in detail.
Mechanism of Action
CJC-1295 binds to the GHRH receptor (GHRH-R) on somatotroph cells in the anterior pituitary gland. Activation of this receptor triggers a Gs-protein-coupled signaling cascade that elevates intracellular cyclic AMP (cAMP) and activates protein kinase A. The downstream result is increased synthesis and pulsatile secretion of growth hormone (GH) from the pituitary into systemic circulation.
It is important to understand that CJC-1295 does not itself contain GH. It amplifies the body's own GH release signals. Research models show that this mechanism preserves a degree of physiological feedback: elevated GH and downstream IGF-1 continue to exert negative feedback on the hypothalamic-pituitary axis, which is one reason researchers consider GHRH analogs to have a different safety profile compared to direct GH administration.
What Research Shows CJC-1295 Does
Published preclinical and early clinical studies have examined several areas where CJC-1295 affects biological parameters. The following is a summary of research-reported observations, not a list of approved clinical uses.
Growth Hormone and IGF-1 Elevation
A 2006 clinical study by Jetté et al. (Journal of Clinical Endocrinology and Metabolism) administered CJC-1295 with DAC to healthy adults and measured dose-dependent increases in mean GH concentration. IGF-1 levels were elevated for up to two weeks following a single injection, demonstrating the compound's extended pharmacokinetic profile. The half-life of the DAC-conjugated form was estimated at 5.8 to 8.1 days in that study.
Interaction with GH Secretagogues
One of the most replicated research findings is the synergy between GHRH analogs and GH secretagogues (GHRPs) such as ipamorelin. GHRH acts on one receptor (GHRH-R) while ghrelin mimetics act on a separate receptor (GHSR-1a). When both pathways are activated simultaneously, the GH pulse is considerably larger than either compound produces alone. This combination is detailed in the ipamorelin protocol, and the CJC-1295/ipamorelin dosage guide covers research-reported figures for stack studies.
Body Composition Research
Elevated GH and IGF-1 in research subjects is associated with changes in fat oxidation and lean tissue metabolism. Animal and early human studies using CJC-1295 have noted shifts in body composition metrics. For a focused look at this angle, see the article on CJC-1295 and muscle growth research.
CJC-1295 Without DAC vs. With DAC: Different Research Profiles
The two forms of CJC-1295 produce different patterns of GH release, and researchers choose between them depending on the experimental design.
| Parameter | CJC-1295 Without DAC (Mod GRF 1-29) | CJC-1295 With DAC |
|---|---|---|
| Approximate half-life | 25-30 minutes | 5-8 days |
| GH release pattern | Pulsatile, mimics natural GHRH burst | Sustained elevation, broader bleed |
| Dosing frequency in research | Multiple times daily or timed to sleep | Once or twice weekly |
| Common research stack | Typically paired with ipamorelin or GHRP-2 | Used alone or with GHRP in weekly protocols |
Note: figures above are research-reported ranges from preclinical and Phase I data. They are not dosing instructions.
Downstream Effects on GH Axis
Once CJC-1295 triggers GH secretion from the pituitary, the GH travels to the liver and peripheral tissues. The liver responds by producing IGF-1 (insulin-like growth factor 1), which mediates many of the growth-related effects studied in research. IGF-1 from the liver circulates and acts on muscle, bone, and adipose tissue. Researchers interested in this downstream signaling often reference our IGF-1 LR3 protocol when comparing direct IGF-1 administration to indirect stimulation via GHRH analogs.
What CJC-1295 Does Not Do
Understanding the boundaries of CJC-1295's mechanism is as important as understanding what it activates. Several common misconceptions appear in research community discussions:
- CJC-1295 does not directly stimulate muscle protein synthesis. It elevates GH, which in turn affects IGF-1, which then influences anabolic signaling.
- It does not suppress cortisol or sex hormones directly. Any downstream hormonal changes are secondary effects of GH axis modulation.
- It does not produce the ghrelin-mediated appetite stimulation seen with GHRP peptides such as GHRP-6. If appetite effects are observed in research subjects, they are usually attributed to a co-administered GHRP rather than CJC-1295 itself.
Reconstitution and Handling in Research
CJC-1295 is supplied as a lyophilized (freeze-dried) powder. Before use in a research setting, it is reconstituted with bacteriostatic water or sterile water for injection. Accurate reconstitution is important because the compound is dosed in micrograms per kilogram of research subject body weight in most studies. The peptide calculator on this site helps researchers calculate precise volumes from known vial mass and added diluent volume. A general primer on reconstitution technique is available in the protocols section.
Summary
CJC-1295 is a GHRH receptor agonist engineered for extended plasma stability. Its primary research-documented action is amplification of pulsatile GH secretion from the anterior pituitary, with downstream elevation of hepatic IGF-1. The DAC-conjugated form extends this effect over days rather than minutes. Researchers most often study it in combination with GHRP peptides to maximize the amplitude of GH pulses. All applications described here are confined to laboratory and preclinical research contexts.